Abstract

Aggregated and highly phosphorylated tau protein is a pathological hallmark of Alzheimer's disease (AD) and other tauopathies. We identified motifs of alternating polar and apolar amino acids within the microtubule-binding repeats of tau which were interrupted by small breaking stretches. Minimal mutation of these breaking sequences yielded a unique instantly aggregating tau mutant containing longer stretches of polar/apolar amino acids without losing its microtubule-binding capacity. These modifications produced rapid aggregation and cytotoxicity with accompanying occurrence of pathologic tau phosphoepitopes (AT8, AT180, AT270, AT100, Ser(422), and PHF-1) and conformational epitopes (MC-1 and Alz50) in cells. Similar to pathological tau in the pretangle state, toxicity appeared to occur early without the requirement for extensive fibril formation. Thus, our mutant protein provides a novel platform for the investigation of the molecular mechanisms for toxicity and cellular behavior of pathologically aggregated tau proteins and the identification of its interaction partners.

Highlights

  • Aggregates of hyperphosphorylated tau protein are a pathological hallmark of many neurodegenerative diseases, which include Alzheimer disease (AD),3 frontotemporal dementia with Parkinson syndrome linked to chromosome 17 (FTDP17), and others [1, 2]

  • It has been shown that the third microtubule-binding repeats (MTBRs) contains a sequence that aggregates in isolated form [6], and the MTBRs have been shown to be located in the core of fibrils by tryptophan fluorescence scanning spectroscopy [4]

  • Modification of MTBRs Producing an Instantly Aggregating Tau Mutant—We identified motifs of 4 or 5 amino acids consisting of alternating polar/apolar residues in the second, third, and fourth MTBR of the 441-amino acid-long form of human wild-type tau (WT-tau) (Fig. 1, upper panel)

Read more

Summary

Introduction

Aggregates of hyperphosphorylated tau protein are a pathological hallmark of many neurodegenerative diseases, which include Alzheimer disease (AD),3 frontotemporal dementia with Parkinson syndrome linked to chromosome 17 (FTDP17), and others [1, 2]. We found a 2–3-fold increase in labeling intensity for PHF-1, AD2 (not shown), and Ser422 antibodies in 3PO-tau-expressing cells (Fig. 4C).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call